A BILL 
To reauthorize the Stem Cell Therapeutic and Research Act 
of 2005, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Timely ReAuthoriza-
4
tion of Necessary Stem-cell Programs Lends Access to 
5
Needed Therapies Act of 2021’’ or the ‘‘TRANSPLANT 
6
Act of 2021’’. 
7
22:20 Mar 05, 2021
H941
2 
•HR 941 IH
SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL 
1
TRANSPLANTATION PROGRAM. 
2
(a) ADVISORY COUNCIL MEETINGS.—Subsection (a) 
3
of section 379 of the Public Health Service Act (42 U.S.C. 
4
274k) is amended by adding at the end the following new 
5
paragraph: 
6
‘‘(7) The Secretary shall convene the Advisory 
7
Council at least two times each calendar year.’’. 
8
(b) INCREASING COLLECTION.— 
9
(1) TECHNICAL CLARIFICATION.—Effective as 
10
if included in the enactment of Public Law 114–104 
11
(the Stem Cell Therapeutic and Research Reauthor-
12
ization Act of 2015), the amendment to section 
13
379(d)(2)(B) of the Public Health Service Act (42 
14
U.S.C. 274k(d)(2)(B)) in section 2(a)(2) of Public 
15
Law 114–104 is amended by inserting ‘‘goal of in-
16
creasing collections of high quality’’ before ‘‘cord 
17
blood units,’’. 
18
(2) ELIMINATING
DEADWOOD.—Subparagraph 
19
(B) of section 379(d)(2) of the Public Health Serv-
20
ice Act (42 U.S.C. 274k(d)(2)) is amended by strik-
21
ing the second and third sentences in such subpara-
22
graph. 
23
(c) PERIODIC REVIEW OF STATE OF SCIENCE.—Sec-
24
tion 379 of the Public Health Service Act (42 U.S.C. 
25
22:20 Mar 05, 2021
H941
3 
•HR 941 IH
274k) is amended by adding at the end the following new 
1
subsection: 
2
‘‘(o) PERIODIC REVIEW OF STATE OF SCIENCE.— 
3
‘‘(1) REVIEW.—Not less frequently than every 
4
2 years, the Secretary, in consultation with the Di-
5
rector of the National Institutes of Health, the Com-
6
missioner of Food and Drugs, the Administrator of 
7
the Health Resources and Services Administration, 
8
the Advisory Council, and other stakeholders, where 
9
appropriate given relevant expertise, shall conduct a 
10
review of the state of the science of using adult stem 
11
cells and birthing tissues to develop new types of 
12
therapies for patients, for the purpose of considering 
13
the potential inclusion of such new types of therapies 
14
in the Program. 
15
‘‘(2) 
RECOMMENDATIONS.—Not 
later 
than 
16
June 30, 2025, the Secretary shall— 
17
‘‘(A) complete the second review required 
18
by paragraph (1); and 
19
‘‘(B) informed by such review, submit to 
20
the Committee on Health, Education, Labor, 
21
and Pensions of the Senate and the Committee 
22
on Energy and Commerce of the House of Rep-
23
resentatives recommendations on the appro-
24
22:20 Mar 05, 2021
H941
4 
•HR 941 IH
priateness of the inclusion of new types of 
1
therapies in the Program.’’. 
2
(d) AUTHORIZATION OF APPROPRIATIONS.—Section 
3
379B of the Public Health Service Act (42 U.S.C. 274m) 
4
is amended by striking ‘‘$33,000,000 for fiscal year 2015 
5
and $30,000,000 for each of fiscal years 2016 through 
6
2020’’ and inserting ‘‘$31,009,000 for each of fiscal years 
7
2022 through 2026’’. 
8
SEC. 3. CORD BLOOD INVENTORY. 
9
Subsection (g) of section 2 of the Stem Cell Thera-
10
peutic and Research Act of 2005 (42 U.S.C. 274k note) 
11
is amended to read as follows: 
12
‘‘(g) AUTHORIZATION
OF
APPROPRIATIONS.—To 
13
carry out this section, there is authorized to be appro-
14
priated $23,000,000 for each of fiscal years 2022 through 
15
2026.’’. 
16
SEC. 4. ADVANCING THE FIELD OF REGENERATIVE MEDI-
17
CINE. 
18
Section 402 of the Public Health Service Act (42 
19
U.S.C. 282) is amended by adding at the end the fol-
20
lowing: 
21
‘‘(o) REGENERATIVE MEDICINE.—The Director of 
22
NIH shall, as appropriate, continue to consult with the 
23
directors of relevant institutes and centers of the National 
24
Institutes of Health, other relevant experts from such in-
25
22:20 Mar 05, 2021
H941
5 
•HR 941 IH
stitutes and centers, and relevant experts within the Food 
1
and Drug Administration, to further the field of regenera-
2
tive medicine using adult stem cells, including autologous 
3
stem cells, therapeutic tissue engineering products, human 
4
cell and tissue products, human gene therapies, and ge-
5
netically modified cells.’’. 
6
SEC. 5. GAO REPORT ON REGENERATIVE MEDICINE WORK-
7
FORCE. 
8
Not later than 2 years after the date of enactment 
9
of this Act, the Comptroller General of the United States 
10
shall submit to the Committee on Health, Education, 
11
Labor, and Pensions of the Senate and the Committee on 
12
Energy and Commerce of the House of Representatives 
13
a report that assesses a specialized health care workforce 
14
in the field of regenerative medicine. The report shall in-
15
clude— 
16
(1) an overview of the current employment lev-
17
els, in both commercial and academic settings, for— 
18
(A) positions necessary for the collection 
19
and transplantation of stem cell therapeutics, 
20
including bone marrow and cord blood; and 
21
(B) positions in the field of regenerative 
22
medicine using adult stem cells and related to 
23
product development; 
24
22:20 Mar 05, 2021
H941
6 
•HR 941 IH
(2) the identification of gaps, if any, in the pro-
1
jected workforce capacity for— 
2
(A) positions described in paragraph 
3
(1)(A); and 
4
(B) the field of regenerative medicine using 
5
adult stem cells, including workforce gaps re-
6
lated to the development of new cellular thera-
7
pies using adult stem cells; 
8
(3) an overview of the availability of training 
9
programs related to the development, refinement, 
10
and utilization of adult stem cells, including training 
11
on good manufacturing practices for such activities, 
12
and the performance of such programs; and 
13
(4) recommendations, if any, for improving the 
14
workforce capacity related to— 
15
(A) the positions described in paragraph 
16
(1)(A); or 
17
(B) the field of regenerative medicine using 
18
adult stem cells. 
19
Æ 
22:20 Mar 05, 2021
H941
